Display options
Share it on

Health Serv Res Manag Epidemiol. 2015 Oct 07;2:2333392815609061. doi: 10.1177/2333392815609061. eCollection 2015.

Chronic Disease Prevalence and Medicare Advantage Market Penetration: Findings From the Medical Expenditure Panel Survey.

Health services research and managerial epidemiology

Steven W Howard, Stephanie Lazarus Bernell, Faizan M Casim, Jennifer Wilmott, Lindsey Pearson, Caitlin M Byler, Zidong Zhang

Affiliations

  1. Health Management and Policy, Saint Louis University, St Louis, MO, USA.
  2. School of Social and Behavioral Health Sciences, Corvallis, OR, USA.
  3. USDA Food and Nutrition Service, VA, USA.
  4. Biostatistics, Saint Louis University, St Louis, MO, USA.
  5. St Luke's Health System, Kansas City, MO, USA.
  6. University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  7. Jefferson County Health Department, MO, USA.

PMID: 28462266 PMCID: PMC5266451 DOI: 10.1177/2333392815609061

Abstract

By March 2015, 30% of all Medicare beneficiaries were enrolled in Medicare Advantage (MA) plans. Research to date has not explored the impacts of MA market penetration on individual or population health outcomes. The primary objective of this study is to examine the relationships between MA market penetration and the beneficiary's portfolio of cardiometabolic diagnoses. This study uses 2004 to 2008 Medical Expenditure Panel Survey (MEPS) Household Component data to construct an aggregate index that captures multiple diagnoses in one outcome measure (Chronic Disease Severity Index [CDSI]). The MEPS data for 8089 Medicare beneficiaries are merged with MA market penetration data from Centers for Medicare and Medicaid Services (CMS). Ordinary least squares regressions are run with SAS 9.3 to model the effects of MA market penetration on CDSI. The results suggest that each percentage increase in MA market penetration is associated with a greater than 2-point decline in CDSI (lower burden of cardiometabolic chronic disease). Spill-over effects may be driving improvements in the cardiometabolic health of beneficiary populations in counties with elevated levels of MA market penetration.

Keywords: MEPS; Medicare Advantage; cardiometabolic conditions; cardiovascular disease; diabetes; market penetration; spill-over effects

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

  1. Inquiry. 2004 Summer;41(2):144-58 - PubMed
  2. Health Econ. 2002 Oct;11(7):571-84 - PubMed
  3. J Health Econ. 2003 Nov;22(6):915-31 - PubMed
  4. J Health Econ. 2008 Dec;27(6):1451-61 - PubMed
  5. Am Heart J. 2007 Dec;154(6):1153-9 - PubMed
  6. Health Serv Res. 2006 Aug;41(4 Pt 1):1181-99 - PubMed
  7. Health Serv Res. 2007 Apr;42(2):682-705 - PubMed
  8. Med Care Res Rev. 2006 Dec;63(6 Suppl):112S-140S - PubMed
  9. Med Care. 2005 May;43(5):500-6 - PubMed
  10. Health Aff (Millwood). 2004 Jul-Dec;Suppl Web Exclusives:W4-572-85 - PubMed
  11. Med Care Res Rev. 2006 Dec;63(6 Suppl):56S-89S - PubMed
  12. J Health Econ. 1997 Aug;16(4):453-81 - PubMed
  13. Health Serv Res. 2004 Feb;39(1):131-52 - PubMed
  14. Health Serv Res. 2004 Dec;39(6 Pt 1):1751-72 - PubMed

Publication Types